RxSight, Inc. (RXST)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 15 | 23 | 49 | 89 | 140 | 134 | 128 | 147 |
| Operating profit | $m | -48 | -55 | ||||||
| Net profit | $m | 28 | -49 | -67 | -49 | -27 | -39 | -47 | -39 |
| EPS reported | $ | -0.95 | -1.13 | ||||||
| Operating cashflow per share | $ | -0.38 | -0.55 | ||||||
| Capex per share | $ | 0.09 | 0.11 | ||||||
| FCF per share | $ | -0.47 | -0.65 | ||||||
| Free cash flow | $m | -19 | -27 | ||||||
| Net debt | $m | -218 | -209 | ||||||
| Book value equity | $m | 276 | 263 | ||||||
| Book value per share | $ | 6.70 | 6.35 | ||||||
| Number of shares | m | 41.18 | 41.49 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.56 | 1.63 | ||||||
| P/S LTM | x | 3.19 | 3.36 | ||||||
| P/FCF LTM | x | -22.18 | -15.79 | ||||||
| EV/EBITDA LTM | x | -10.82 | -9.71 | ||||||
| EV/Sales LTM | x | 3.12 | 2.21 | ||||||
| Earnings Yield LTM | % | -9.08% | -16.42% | ||||||
| FCF Yield | % | -4.51% | -6.33% | ||||||
| Quality | |||||||||
| ROE | % | -14.13% | -17.35% | ||||||
| ROIC | % | -16.81% | -20.12% | ||||||
| Operating margin | % | -35.84% | -43.20% | ||||||
| Gross margin | % | +76.60% | +77.50% | ||||||
| FCF/Sales | % | -14.38% | -21.29% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -3.89% | -8.82% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.75 | -2.57 | ||||||
| Net Debt/EBITDA | x | 0.23 | 0.06 | ||||||
| EBIT/Net interest | x | -1,204.75 | -3,674.20 | ||||||
| Net debt/market cap | % | +2.30% | 0.00% | ||||||
| Net debt/Equity | x | -0.79 | -0.79 | ||||||
| Gross debt/equity | x | 0.04 | 0.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free